Trial Profile
Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Switch Followed by Sofosbuvir/Velpatasvir (SOF/VEL) Antiviral HCV Therapy Followed by Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Simplification in HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy - A Pilot Feasibility Study
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 02 Dec 2021
Price :
$35
*
At a glance
- Drugs Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary) ; Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C; HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- 30 Oct 2021 Results (n=22) assessing safety and efficacy of elvitegravir/cobicistat/emt ricit - abine/tenofovir alafenamide switch followed by SOF/VEL antiviral HCV therapy followed by B/F/TAF simplification in HIV- HCV co- infected subjects receiving opioid agonist therapy with methadone or buprenorphine / naloxone, presented at the 18th European AIDS Conference.
- 23 Dec 2019 Planned End Date changed from 30 Jun 2019 to 22 Jun 2021.
- 23 Dec 2019 Planned primary completion date changed from 30 Jun 2019 to 21 Jul 2020.